Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trials
Authors' conclusion
Rezafungin was well tolerated and efficacious in critically ill, mainly non-neutropenic patients with candidaemia and/or IC.
Study context
- Population
- Adults with candidaemia and/or invasive candidiasis in the intensive care unit (ICU) at randomisationICU subset of 294
- Participants
- 113 adults
- Comparison
- Rezafungin vs caspofungin
- Rezafunginn = 46
- Caspofunginn = 67reference
- Outcome
- All-cause mortality
- Follow-up
- Day 30
Methodological detailsdouble-blind
- Double-blind
Pooled result
As reported in the abstract
Day 30 all-cause mortality
Further pooled results
Mycological eradication · Day 5
Mycological eradication · Day 14
Time to negative blood culture · nominal, not adjusted for multiplicity
P = 0.001
Events
| Outcome | Rezafungin | Caspofungin |
|---|---|---|
| Candidaemia/IC-attributable deaths | 2 | 1 |
Rezafungin exposure after initial 400-mg dose, ICU (n = 50) vs non-ICU (n = 117)
- Comparable between ICU and non-ICU patients
Safety
Discontinuation due to treatment-emergent adverse events
Discontinuation due to treatment-emergent adverse events
- Safety profiles similar between groups
Original publication
Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trials. Crit Care. Published 28 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →